BUZZ - Citi remains cautious about the revival of ARB, while Morningstar is optimistic about its value
路透社2026/10/15 22:21October 15 - ** Citi maintains its "Neutral" rating on ARB Corporation ARB.AX and lowers its target price to 17.95 AUD, citing weaker-than-expected sales and ongoing uncertainty over when vehicle supply issues will normalize.
** The broker cuts its earnings per share (EPS) forecasts for fiscal years 2027 and 2028 by 5% and 6%, respectively, reflecting a slowdown in sales trends.
** Notes that supply disruptions are affecting Toyota Hilux and Ford Ranger models.
** Adds that rising fuel prices and interest rates continue to dampen discretionary demand.
** Points out that supply recovery for the Ford Ranger appears to be underway, but the outlook for a rebound in Toyota sales remains unclear.
** Morningstar maintains its fair value estimate for ARB at 25 AUD, stating that the market is overly focused on cyclical weakness in consumer confidence and declines in sales of key models.
** Notes that ARB has pricing power in Australia and expects earnings growth to get back on track as domestic profit margins recover and sales of main pickup models improve.
** Adds that ARB’s share price is undervalued and expects earnings growth to resume as domestic profit margins rebound from cyclical lows.
** As of the last close, ARB has fallen 47.3% so far this year.
(To facilitate non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain inaccuracies or lack context, Reuters does not guarantee the accuracy of these translations and provides them solely for reader convenience. Reuters accepts no liability for any damages or losses that may arise from using the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
No scientific evidence but viral on social media: “Bodybuilding miracle drug” peptide products deregulation file sent to the White House for review, Hims&Hers (HIMS.US) surged 6% in one day.
The temporary admission policy for peptides has been submitted to the White House for review, and compounding pharmacies are expected to receive approval to produce BPC-157 and other substances; HIMS closed up 6% on Thursday.
AiCoin丨10.16 Snapshot: PPI Exceeds Expectations, Russia Bans P2P, US Stock ETF Net Outflow
Yen barely gains on a BoJ push for hikes and a Tokyo stock rout

IEA agrees to release of outstanding 100 million barrels of oil
